The Roadmap Special Edition Report on Dolutegravir The Roadmap Special Edition Report on Dolutegravir – I-MAK

The Roadmap Special Edition Report on Dolutegravir

1 Jun 2017
View Resource

This report expands on the information provided in the original Roadmap to equip stakeholders with current clinical, cost, and patent information to inform decision-making about the best strategies to expand currently limited access to DTG.

Partner with us now to build
a more just and equitable
medicine system for all.